Claims

1. A compound of formula (I)



(I)

wherein:



and  are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

A is -O-, -S-, -SO-, $-SO_2$-, $-NR_{13}$-, -C(O)-, $-N(R_{14})C(O)$-, $-C(O)N(R_{15})$-, $-N(R_{14})C(O)N(R_{15})$-, $-C(R_{14})$=N-,







a chemical bond,



or



B is –O-, -S-, $-NR_{19}$-, a chemical bond, -C(O)-, $-N(R_{20})C(O)$-, or $-C(O)N(R_{20})$-;

E is a chemical bond or an ethylene group;

a is 0-6;

b is 0-4;

c is 0-4;

d is 0-6;

g is 1-5;

h is 1-4;

R_1, R_3, R_5 and R_7, are independently hydrogen, halogen, alkyl, carboxyl, alkoxycarbonyl or aralkyl;

R_2, R_4, R_6 and R_8, are independently $-(CH_2)_q$-X;

q is 0-3;

X is hydrogen, halogen, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, aralkoxy, heteroaralkoxy, carboxyl, alkoxycarbonyl, tetrazolyl, acyl, acylHNSO$_2$-, -SR$_{23}$, Y^1Y^2N- or Y^3Y^4NCO-;

Y^1 and Y^2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or one of Y^1 and Y^2 is hydrogen or alkyl and the other of Y^1 and Y^2 is acyl or aroyl;

Y^3 and Y^4 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl;

Z is $R_{21}O_2C$-, $R_{21}OC$-, cyclo-imide, -CN, $R_{21}O_2SHNCO$-, $R_{21}O_2SHN$-, $(R_{21})_2NCO$-, $R_{21}O$- 2,4-thiazolidinedionyl, or tetrazolyl; and

~~R_{15} and~~ R_{21} ~~are~~ independently hydrogen, alkyl, aryl, cycloalkyl, or aralkyl;

R_{13}, ~~R_{17}~~, R_{19} and R_{23} are independently $R_{22}OC$-, $R_{22}NHOC$-, hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl;

R_{14}, R_{15}, R_{16}, ~~R_{18}~~ and R_{20} are independently hydrogen, alkyl, aralkyl, carbonyl, or alkoxycarbonyl; or R_{14}, and R_{15} taken together with the carbon and nitrogen atoms through which they are linked form a 5 or 6-membered azaheterocyclyl group; or

when a is 2-6, then at least one pair of vicinal R_1 radicals taken together with the carbon atoms to which the R_1 radicals are linked form a  group; or

when b is 2-4, then at least one pair of vicinal R_3 radicals taken together with the carbon atoms to which the R_3 radicals are linked form a  group; or

when c is 2-4, then at least one pair of vicinal R_5 radicals taken together with the carbon atoms to which the R_5 radicals are linked form a  group; or

when d is 2-6, then at least one pair of vicinal R_7 radicals taken together with the carbon atoms to which the R_7 radicals are linked form a  group, or a 5-membered cycloalkyl group; or

when d is 2-6, then at least one pair of non-vicinal R_7 radicals taken together with the carbon atoms to which the R_7 radicals are linked form a 5-membered cycloalkyl group; or

geminal R_5 and R_6 radicals taken together with the carbon atom through which these radicals are linked form a 5 membered cycloalkyl group; or

geminal R_7 and R_8 radicals taken together with the carbon atom through which these radicals are linked form a 5 membered cycloalkyl group; and

R_{22} is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl; or

a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

2. A compound according to claim 1 wherein Ar I is optionally substituted aryl, optionally substituted azaheteroaryl, or optionally substituted fused arylheterocyclenyl or fused arylheterocyclyl; and Ar II is optionally substituted phenyl or optionally substituted naphthyl, optionally substituted heteroaryl, or optionally substituted fused arylheterocyclenyl.

3. A compound according to claim 1 wherein a = 1 or 2; R_1 and R_2 is hydrogen; A is a chemical bond; and b = 0.

4. A compound according to claim 1 wherein a = 0, 1, or 2, A is $-C(O)N(R^{15})-$ or $-N(R^{14})C(O)-$, and b = 0 or 1.

5. A compound according to claim 1 wherein R_1 and R_2 are both hydrogen, a = 1, A is –O- and b = 0.

6. A compound according to claim 1 wherein R_1 and R_2 are both hydrogen, a = 2, A is –O- and b = 0.

7. A compound according to claim 1 wherein a = 0, A is –O- or $-NR_{13}-$; R_{13} is hydrogen or alkyl; R_3 and R_4 are both independently hydrogen; and b = 1.

8. A compound according to claim 1 wherein a = 0; A is  or  ; R_{15} and R_{16} are hydrogen; g is 1, 2, 3 or 4; and b = 0.

9. A compound according to claim 1 wherein a = 0; A is $-NR_{13}-$, b = 1, R_3 and R_4 are hydrogen, and R_{13} is hydrogen, alkyl, or $R_{22}(O=)C-$.

10. A compound according to claim 1 wherein a = 2; then the vicinal R_1 radicals taken together with the carbon atoms through which these radicals are linked form a  group; R_2 is hydrogen; A is a chemical bond or –O-; and b=0.

11. A compound according to claim 1 wherein a = 6; then at least one pair of vicinal R_1 radicals taken together with the carbon atoms through which these radicals are linked form a  group; R_2 is hydrogen or alkyl; A is –O-; and b=0.

12. A compound according to claim 1 wherein a = 1, 2 or 3; R_1 and R_2 are hydrogen; A is -O-; and b = 0.

13. A compound according to claim 1 wherein a = 1; R_1, R_2, R_3 and R_4 are hydrogen; A is -O-; and b = 1.

14. A compound according to claim 1 wherein a = 2; A is  ; h = 1 or 2; and b = 0.

15. A compound according to claim 1 wherein c = 0; d = 0; B and E is a chemical bond; Z is $R_{21}O_2SHNCO$-, and R_{21} is phenyl.

16. A compound according to claim 1 wherein c = 0; d = 2; B is –C(O)N(R_{20})-, E is a chemical bond; Z is a tetrazolyl group or $–CO_2R_{21}$; R_{20} is hydrogen, alkyl, alkoxycarbonyl.

17. A compound according to claim 1 wherein c = 0 or 4; d = 0 or 1; B and E is a chemical bond; Z is tetrazolyl, NH_2CO- or $–CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

18. A compound according to claim 1 wherein c = 0 or 1; d = 0 or 1; B is –O- or a chemical bond; E is a chemical bond; and Z is tetrazolyl, NH_2CO- or $–CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

19. A compound according to claim 1 wherein c = 0; d = 1; B is –O- or a chemical bond; E is a chemical bond; R_7 and R_8 are hydrogen or alkyl; and Z is tetrazolyl, NH_2CO- or $–CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

20. A compound according to claim 1 wherein c = 2 or 4, then at least one pair of vicinal R_5 radicals taken together with the carbon atoms to which the R_5 radicals are linked form a 

group; d = 0; D and E is a chemical bond; and Z is a tetrazolyl group or $-CO_2R_{21}$; and R_{21} is hydrogen.

21. A compound according to claim 1 wherein c = 0; d = 3 or 4; B is -O-; E is a chemical bond; R_7 and R_8 are hydrogen or alkyl, or at least one of R_7 is carboxyl or alkoxycarbonyl; Z is tetrazolyl, $-CO_2R_{21}$ or $(R_{21})_2NC(O)-$; and R_{21} is hydrogen or lower alkyl.

22. A compound according to claim 1 wherein c = 0; d = 1, 2, or 3; B is -C(O)-; E is a chemical bond; R_7 and R_8 are hydrogen or alkyl; Z is tetrazolyl or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

23. A compound according to claim 1 wherein c = 4; d = 0; B and E are a chemical bond; R_7 and R_8 are hydrogen or alkyl; Z is tetrazolyl or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

24. A compound according to claim 1 wherein c = 0, 1 or 2; d = 1, 2 or 3; B is –S- or NR_{19}, E ~~are a~~ is a chemical bond; R_5, R_6, R_7 and R_8 are hydrogen; Z is tetrazolyl or $-CO_2R_{21}$; and R_{21} is hydrogen or lower alkyl.

26. A compound according to claim 1 wherein R_6 and R_8 are $-(CH_2)q-X$; q is 0, 1 or 2; and X is independently hydrogen, aralkyl or lower alkyl.

27. A compound according to claim 1 wherein at least one pair of geminal R_5 and R_6 radicals taken together with the carbon atom through which these radicals are linked form a 5-membered cycloalkyl group.

28. A compound according to claim 1 wherein at least one pair of geminal R_7 and R_8 radicals taken together with the carbon atom through which these radicals are linked form a 5-membered cycloalkyl group.

29. A compound according to claim 1 wherein Z is $-CO_2H$, -CN or a tetrazolyl group.

30. A compound according to claim 1 wherein 

is an optionally substituted quinolinyl, quinoxalinyl, quinazolinyl, isoquinolinyl, *N*-alkyl-quinolin-4-onyl, quinazolin-4-onyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, indolinyl oxazolyl, thiazolyl, oxadiazolyl isoxazolyl, imidazolyl, pyrazol-yl, thiadiazolyl, triazolyl, pyridyl pyrimidinyl, pyrazinyl, pyridazinyl, phenyl, or napthalenyl group, wherein the substituent is a

ring system substituent, ~~more preferably a substituent selected from the group consisting of phenyl, substituted-phenyl, thienyl, substituted thienyl, cycloalkyl, lower alkyl, branched alkyl, fluoro, chloro, alkoxy, aralkyloxy, trifluoromethyl and trifluoromethyloxy.~~

31. A compound according to claim 1 wherein Ar1 is unsubstituted quinolin-2-yl, 3-substituted quinolin-2-yl, 4-substituted quinolin-2-yl, 6-substituted quinolin-2-yl or 7 substituted quinolin-2-yl; an unsubstituted quinozalin-2-yl, 3-substituted quinozalin-2-yl, 6-substituted quinozalin-2-yl or 3,6-disubstituted quinozalin-2-yl; unsubstituted quinazolin-2-yl, 4-substituted quinazolin-2-yl or 6-substituted quinazolin-2-yl; unsubstituted isoquinolin-3-yl, 6-substituted isoquinolin-3-yl or 7-substituted isoquinolin-3-yl; 3-substituted-quinazolin-4-on-2-yl; *N*-substituted quinolin-4-on-2-yl; 2-substituted-oxazol-4-yl or 2,5 disubstituted-oxazol-4-yl; 4-substituted oxazol-2-yl or 4,5-disubstituted-oxazol-2-yl; 2-substituted thiazol-4-yl or 2,5-disubstituted thiazol-4-yl; 4-substituted thiazol-2-yl or 4,5-disubstituted-thiazol-2-yl; 5-substituted-[1,2,4]oxadiazol-3-yl; 3-substituted-[1,2,4] oxadiazol-5-yl; 5-substituted-imidazol-2-yl or 3,5-disubstituted-imidazol-2-yl; 2-substituted-imidazol-5-yl or 2,3-disubstituted-imidazol-5-yl; 3-substituted-isoxazol-5-yl; 5-substituted-isoxazol-3-yl; 5-substituted-[1,2,4] thiadiazol-3-yl; 3-substituted-[1,2,4]-thiadiazol-5-yl; 2-substituted-[1,3,4]-thiadiazol-5-yl; 2-substituted-[1,3,4]-oxadiazol-5-yl; 1-substituted-pyrazol-3-yl; 3-substituted-pyrazol-5-yl; 3-substituted-[1,2,4]-triazol-5-yl; 1-substituted-[1,2,4]-triazol-3-yl; 3-substituted pyridin-2-yl, 5-substituted pyridin-2-yl, 6-substituted pyridin-2-yl or 3,5-disubstituted pyridin-2-yl; 3-substituted pyrazin-2-yl, 5-substituted pyrazin-2-yl, 6-substituted pyrazin-2-yl or 3,5 disubstituted-pyrazin-2-yl; 5-substituted pyrimidin-2-yl or 6-substituted-pyrimidin-2-yl; 6-substituted-pyridazin-3-yl or 4,6-disubstituted-pyridazin-3-yl; unsubstituted napthalen-2-yl, 3-substituted napthalen-2-yl, 4-substituted napthalen-2-yl, 6-substituted napthalen-2-yl or 7 substituted napthalen-2-yl; 2-substituted phenyl, 4-substituted phenyl or 2,4-disubstituted phenyl; unsubstituted -benzothiazol-2-yl or 5-substituted-benzothiazol-2-yl; unsubstituted benzoxazol-2yl or 5-substituted-benzoxazol-2yl; unsubstituted -benzimidazol-2-yl or 5-substituted-benzimidazol-2-yl; unsubstituted -thiophen-2yl, 3-substituted -thiophen-2yl, 6-substituted -thiophen-2yl or 3,6-disubstituted-thiophen-2yl; unsubstituted -benzofuran-2-y, 3-substituted-benzofuran-2-yl, 6-substituted-benzofuran-2-yl or 3,6-disubstituted-benzofuran-2-yl; 3-substituted-benzofuran-6-yl or 3,7-disubstituted-benzofuran-6-yl, wherein the substituent is a ring system substituent, ~~more preferably a substituent selected from the~~ group consisting of phenyl, ~~substituted-phenyl, thienyl,~~

C4 cont ~~substituted thienyl, cycloalkyl, lower alkyl, branched alkyl, fluoro, chloro, alkoxy, aralkyloxy, trifluoromethyl and trifluoromethyloxy.~~

32. A compound according to claim 1 wherein a = 0, A is –O- or -NR_{13}-; R_{13} is hydrogen or alkyl; R_3 and R_4 are both independently hydrogen; b = 1; and ArI is 3-substituted quinolin-2-yl, 4-substituted quinolin-2-yl, 6-substituted quinolin-2-yl, 7 substituted quinolin-2-yl, unsubstituted quinoxalin-2-yl, 3-substituted quinoxalin-2-yl, 6-substituted quinoxalin-2-yl, 3,6-disubstituted quinoxalin-2-yl, unsubstituted quinazolin-2-yl, 4-substituted quinazolin-2-yl, 6-substituted quinazolin-2-yl, unsubstituted isoquinolin-3-yl, 6-substituted isoquinolin-3-yl, 7-substituted isoquinolin-3-yl, 4-substituted oxazol-2-yl, 4,5-disubstituted-oxazol-2-yl, 4-substituted-thiazol-2-yl, 4,5-disubstituted-thiazol-2-yl, 5-substituted -imidazol-2-yl, 3,5-disubstituted-imidazol-2-yl, 1-substituted-pyrazol-3-yl, 3-substituted-pyrazol-5-yl, 3-substituted pyridin-2-yl, 5-substituted pyridin-2-yl, 6-substituted pyridin-2-yl or 3,5-disubstituted pyridin-2-yl, 3-substituted pyrazin-2-yl, 5-substituted pyrazin-2-yl, 6-substituted pyrazin-2-yl, 3,5 disubstituted-pyrazin-2-yl, 5-substituted pyrimidin-2-yl, 6-substituted-pyrimidin-2-yl, 6-substituted-pyridazin-3-yl, 4,6-disubstituted-pyridazin-3-yl, unsubstituted-benzothiazol-2-yl, 5-substituted-benzothiazol-2-yl, unsubstituted-benzoxazol-2-yl, 5-substituted-benzoxazol-2-yl, unsubstituted benzimidazol-2-yl, 5-substituted-benzimidazol-2-yl, 3-substituted-benzofuran-6-yl or 3,7-disubstituted-benzofuran-6-yl.

33. A compound according to claim 1 wherein formula I as described by formula (Ia) below:



(Ia)

wherein



is independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

a = 1;

b = 0;

R_1 and R_2 are hydrogen

A is –O-;

R_5, R_6, R_7, R_8 are hydrogen;

c = 0;

d = 0;

B and E are a chemical bond;

Z is $R_{21}O_2C$-, $R_{21}OC$-, cyclo-imide, -CN, $R_{21}O_2SHNCO$-, $R_{21}O_2SHN$-, $(R_{21})_2NCO$-, $R_{21}O$- 2,4-thiazolidinedionyl, or tetrazolyl;

R' and R" are ring system substituents, ~~more preferably, R' is hydrogen, lower alkyl, halo, alkoxy, aryloxy or aralkyloxy; and R" is lower alkyl, hydrogen, aralkyloxy, alkoxy, cycloalkylalkyloxy or halo~~.

34. A compound according to claim 33 wherein  is independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

a = 1;

A is  ;

g = 2, 3, 4 or 5;

R_1, R_2, R_3, R_4, R_{15} and R_{16} are hydrogen;

b = 0 or 1;

c = 0;

d = 0;

B and E are a chemical bond;

Z is $-CO_2H$;

R' and R'' are ring system substituents, ~~more preferably, R' is hydrogen, lower alkyl, halo, alkoxy, aryloxy or aralkyloxy; and R'' is lower alkyl, alkoxy, aralkoxy, cycloalkylalkoxy or halo~~.

35. A compound according to claim 33 wherein



is independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

a = 1;



A is ;

g = 2, 3, 4 or 5;

R_1, R_2, R_3, R_4, R_{15} and R_{16} are hydrogen;

b = 0 or 1;

c = 0;

d = 0;

B and E are a chemical bond;

Z is $-CO_2H$;

R' is hydrogen; and R'' is lower alkyl.

36. A compound according to claim 33 wherein



is independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

a = 1;



A is ;

g = 2, 3, 4 or 5;

R_1, R_2, R_3, R_4, R_{15} and R_{16} are hydrogen;

R_7 and R_8 are independently hydrogen;

b = 0 or 1;

c = 0;

d = 0 or 1;

B and E are a chemical bond;

Z is $-CO_2H$;

R' and R" are ring system substituents, ~~more preferably, R' is hydrogen, lower alkyl, halo, alkoxy, aryloxy or aralkyloxy; and R" is lower alkyl, alkoxy, aralkoxy, cycloalkylalkoxy or halo.~~

37. A compound according to claim 33 wherein



is independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

a = 1;

A is 

;

g = 2, 3, 4 or 5;

R_1, R_2, R_3, R_4, R_{15} and R_{16} are independently hydrogen;

R_7 and R_8 are hydrogen

b = 0 or 1;

c = 0;

d = 0 or 1;

B and E are a chemical bond;

Z is $-CO_2H$;

R' is hydrogen; and R" is lower alkyl.

38. A compound according to claim 33 wherein

a = 0-2;

b = 0-1;

A is -O- or $-NR_{13}$-;

R_1, R_2, R_3 and R_4 are independently hydrogen;

R_{13} is hydrogen, $R_{22}OC$-, or alkyl;

c = 0;

d = 0;

B and E are a chemical bond;

Z is $-CO_2H$;

R' and R" are ring system substituents, more preferably, R' is lower alkyl, halo, alkoxy, aryloxy or aralkyl; and R" is lower alkyl or halo.

39. A compound according to claim 33 wherein

a = 1 or 2;

A is -O-;

b = 0;

R_1, R_2, R_7 and R_8 are independently hydrogen;

c = 0;

d = 1;

B and E are a chemical bond;

R' is hydrogen, halo or benzyloxy;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

40. A compound according to claim 33 wherein

a = 1 or 2;

A is -O-;

b = 0;

R_1, R_2, R_7 and R_8 are independently hydrogen;

c = 0;

d = 1;

B and E are a chemical bond;

R' is hydrogen, halo or benzyloxy;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

41. A compound according to claim 33 wherein

a = 1 or 2;

A is -O-;

b = 0;

R_1, R_2, R_7, R_8 are independently hydrogen;

c = 0;

B is -O-;

d = 1;

B and E are a chemical bond;

R' is halo;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

42. A compound according to claim 33 wherein

a = 1;

R_1 and R_2 are hydrogen

A is -O-;

b = 0;

c = 0;

d = 0;

B and E are a chemical bond;

R' is hydrogen, aralkoxy, or halo;

R" is lower alkyl, preferably methyl;

Z is $-CO_2H$.

43. A compound according to claim 33 wherein

a = 1;

A is -O-;

b = 0;

c = 0;

d = 0;

B and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is $-CO_2H$.

44. A compound according to claim 33 wherein



is aryl or heteroaryl;

a = 1;

A is -O-;

b = 0;

c = 0;

d = 0;

B and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is $-CO_2H$.

45. A compound according to claim 33 wherein



is optionally substituted azaheteroaryl;

a = 1;

A is -O-;

b = 0;

c = 0;

d = 0;

B and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is CO_2H.

46. A compound according to claim 33 wherein



is optionally substituted quinolinyl, or a 5-membered heteroaryl group wherein the heteroaryl group is substituted by optionally substituted phenyl or optionally substituted cyclohexyl;

a = 1;

A is –O-;

b = 0;

c = 0;

d = 0;

B and E are a chemical bond;

R' is hydrogen;

R" is lower alkyl;

Z is CO_2H.

47. A compound the according to claim 1 selected from the group consisting of


;


;



;


;


;


;


;


;


;



;



;


;


;


;

;


;

;

154-155°C

;

;


;

;

164-166°C

;

;

179-180°C

;

;

;


;

;


;

;


156°C
145-149°C
125-126°C
122-124°C
105-106°C
77°C (dec)
160-161°C


211°C
42-43°C
89-91°C
149-150°C
187°C


110-115°C
171-173°C
80-82°C
112-116°C
118-121°C


129-133°C
138°C
177-179°C
54-57°C


90-91°C
90-91°C
98-100°C
123-126°C
262°C (dec)


176-181°C
oil; CHN calc C24H27N5O + 0.5H2O: C70.22, H6.87, N17.06; found C70.10, H7.00, N17.12
95-97°C
133-134°C



5





;



;



;



;







48. A compound the according to claim 1 selected from the group consisting of



;

;

;

;

;

;

;

5





; and

49. A compound the according to claim 1 selected from the group consisting of





and

50. A compound the according to claim 1 selected from the group consisting of


;


;


; and



51. A compound the according to claim 1 selected from the group consisting of


;


;


;



and

52. A compound the according to claim 1 selected from the group consisting of




;and

53. A pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound according to claim 1 and a pharmaceutically acceptable carrier.

54. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 1 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof.

55. A method according to claim 54 wherein the disease is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids (FFA), or triclycerides.

56. The method according to claim 54, wherein the physiological disorder is hyperglycemia.

57. The method according to claim 56, wherein the hyperglycemia is diabetes.

58. The method according to claim 56, wherein the hyperglycemia is Type II diabetes.

59. The method according to claim 54, wherein the physiological disorder is hyperinsulinism.

60. The method according to claim 59, wherein the hyperinsulinism is Syndrome X.

61. The method according to claim 54, wherein the physiological disorder is insulin resistance.

62. The method according to claim 54, wherein the physiological disorder is cardiovascular condition.

63. The method according to claim 62, wherein the cardiovascular condition is atherosclerosis.

64. The method according to claim 54, wherein the physiological disorder is hyperlipidemia.

65. The method according to claim 54, wherein the physiological disorder is hypertension.

66. The method according to claim 54, wherein the physiological disorder is an eating disorder.

67. The method according to claim 54 wherein the mediating is agonistic.

68. The method according to claim 54 wherein the mediating is antagonistic.

69. A method for mediating the activity of PPAR-γ receptor comprising contacting said PPAR-γ receptor with a compound of according to claim 1.

70. A pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound according to claim 33 and a pharmaceutically acceptable carrier.

71. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound according to claim 33 having PPAR ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof.

72. A method according to claim 71 wherein the disorder is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids (FFA), or triclycerides.

73. The method according to claim 71, wherein the physiological disorder is hyperglycemia.

74. The method according to claim 71, wherein the hyperglycemia is diabetes

75. The method according to claim 71, wherein the hyperglycemia is Type II diabetes.

76. The method according to claim 71, wherein the physiological disorder is hyperinsulinism.

77. The method according to claim 76, wherein the hyperinsulinism is Syndrome X.

78. The method according to claim 71, wherein the physiological disorder is insulin resistance.

79. The method according to claim 71, wherein the physiological disorder is cardiovascular disorder.

80. The method according to claim 79, wherein the cardiovascular disorder is atherosclerosis.

81. The method according to claim 71, wherein the physiological disorder is hyperlipidemia.

82. The method according to claim 71, wherein the physiological disorder is hypertension.

83. The method according to claim 71, wherein the physiological disorder is an eating disorder.

84. The method according to claim 71 wherein the mediating is agonistic.

85. The method according to claim 71 wherein the mediating is antagonistic.

86. A method for mediating the activity of PPAR receptor comprising contacting said PPAR receptor with a compound of according to claim 33.

87. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARγ ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of


;

;

;

;

;

;

;

;



; and

88. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARα ligand binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of





;

;



; and



89. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARα and PPARγ binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is of the formula:



;



;



;



and

90. A method of treating a patient suffering from a physiological disorder capable of being modulated by a compound having PPARα and PPARδ binding activity, comprising administering to the patient a pharmaceutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:



; and



add A2

add D1

add C7